J Liver Cancer.
2016 Mar;16(1):1-6. 10.17998/jlc.2016.16.1.1.
Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
- Affiliations
-
- 1Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. baesh@catholic.ac.kr
- KMID: 2198515
- DOI: http://doi.org/10.17998/jlc.2016.16.1.1
Abstract
- Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Complete Response of Single Nodular Large Hepatocellular Carcinoma with Pulmonary Metastasis by Sequential Transarterial Chemoembolization and Sorafenib: A Case Report
- The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Liver resection after sorafenib therapy in advanced hepatocellular carcinoma: a case report
- Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy
